Otsuka Pakistan Limited was incorporated in February 1988 and commenced commercial production of intravenous solutions in September 1989 at its factory in Hub, Balochistan. It commands 25% share of the local market. OPL’s current activities are mainly focused on the manufacturing of I.V. Solutions and marketing them effectively to remain in the lead both in quality and quantity. Therapeutic Drugs are OPL’s second line of business, which consist of Pletaal & Meptin. Meptin is manufactured and Pletaal is repacked by M/s Efroze Chemical Industries (Pvt) Limited and are marketed by OPL. OPL is providing international quality solutions and medicines at the doorsteps of Doctors, Hospitals and Pharmacies. Medical profession in Pakistan is
being benefited from Otsuka Research.